University of Groningen

Transcriptome changes during peanut oral immunotherapy and omalizumab treatment

Bjorkander, Sophia; Merid, Simon Kebede; Brodin, David; Brandstrom, Josef; Fagerstrom-Billai, Fredrik; van Der Heiden, Marieke; Konradsen, Jon R.; Kabesch, Michael; van Drunen, Cornelis M.; Golebski, Korneliusz

Published in:
Pediatric Allergy and Immunology

DOI:
[10.1111/pai.13682](https://doi.org/10.1111/pai.13682)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Bjorkander, S., Merid, S. K., Brodin, D., Brandstrom, J., Fagerstrom-Billai, F., van Der Heiden, M., Konradsen, J. R., Kabesch, M., van Drunen, C. M., Golebski, K., van der Zee, A. H., Potocnik, U., Vijverberg, S. J. H., Nopp, A., Nilsson, C., & Melen, E. (2022). Transcriptome changes during peanut oral immunotherapy and omalizumab treatment. *Pediatric Allergy and Immunology*, 33(1), [e13682]. <https://doi.org/10.1111/pai.13682>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Transcriptome changes during peanut oral immunotherapy and omalizumab treatment

To the Editor,

Peanut allergy is a common food allergy and the main cause of anaphylaxis among children.¹ In recent years, oral immunotherapy has emerged as a promising treatment for children with different IgE-mediated food allergies, although safety issues must be considered.² The main aim of immunotherapy is to induce tolerance or desensitization to an allergen, which otherwise causes an allergic reaction. For oral immunotherapy, this means ingesting the allergen in a controlled manner with gradually increasing dosages. Specifically, peanut oral immunotherapy (pOIT) is able to induce tolerance/desensitization.³ While the pathogenesis of food allergy is relatively well-studied,⁴ mechanisms of OIT-induced tolerance are not well understood. Omalizumab (anti-IgE), which is used as treatment for severe allergic asthma and other IgE-driven allergies, can also facilitate OIT initiation⁵; however, little is known about the involved mechanisms, including possible changes at the transcriptional level. We therefore investigated transcriptional changes in whole blood using RNA-sequencing profiles during omalizumab treatment and pOIT in participants from the FASTX (Food Allergen Suppression Therapy with Xolair®) study previously described.^{5,6}

17 peanut allergic adolescents (age 12–18 years) were included in this study (Table S1). Participants were sampled at treatment start (Baseline) and were then treated with omalizumab at recommended dosages for allergic asthma for an initial 8-week period and for some participants additional periods (total of 16 or 24 weeks) until basophil activation test (BAT/CD-sens)⁷ analysis showed suppressed reactivity to peanut. All participants then underwent an open peanut challenge (pOIT start), before starting peanut OIT (pOIT) in combination with continued omalizumab treatment. The peanut dose was gradually increased until reaching a maintenance dose. Guided by a BAT/CD-sens after 8 weeks on the maintenance dose, participants decreased the omalizumab dose by 50% (Maintenance) and continued to decrease the dose if pOIT was tolerated. Eleven participants were able to tolerate pOIT without omalizumab for >8 weeks and then passed an open peanut food challenge (Final); six participants could not discontinue omalizumab; however, blood samples were obtained after 2–3 years on omalizumab (Final); six participants dropped out of the study (Figure S1). RNA-sequencing was performed on whole blood ($n = 17$) at Baseline, pOIT start, Maintenance and Final timepoints using the NovaSeq 6000 platform. DESeq2 was

used for differential expression analysis of the omalizumab effect and a linear mixed-effect model for analyses during pOIT in combination with omalizumab (pOIT + O) after adjustment for treatment outcome and cell types estimates via deconvolution (Figure S2). For further details on the treatment protocol, methods and statistical analysis, see the Online Appendix and Table S1.

For study participant characteristics at Baseline, see Table S1. To elucidate whether omalizumab treatment alone induced alterations in peripheral blood gene expression, we investigated the two first timepoints, Baseline and pOIT start; however, no significant differences were observed (Figure S3). In the longitudinal analysis (pOIT start to Final), 680 genes associated with pOIT + O at nominal $p < .005$ (Table S2). The Gene Ontology (GO) biological process of these 680 genes is presented in Figure 1A,B. Upregulation of 337 genes was linked to GO terms 'protein regulation and modification', while 'neutrophil degranulation, immune response, phagocytosis and metabolic process' were among the top terms for the 343 downregulated genes. Out of the 680 genes, 16 were differentially expressed at false discovery rate (FDR) adjusted $p < .05$ (Table 1, Figure S4). The three genes with the largest negative and positive coefficients, respectively, are displayed in Figure 1C,D; downregulation of *ASGR2*, *GPBAR1* and *HM13*, and upregulation of *USP44*, *ICOS* and *CDKN2AIP*. Finally, we evaluated the overlap between our 680 pOIT + O-associated genes and peripheral blood gene expression changes associated with acute peanut allergic reactions in a recently published clinical study by Watson et al using the same p -value cut-off ($p < .005$).⁸ Out of our 680 significant genes, 108 genes overlapped with differentially expressed genes found by Watson et al,⁸ mostly with opposite direction, $P_{\text{enrichment}} = 0.0095$ (Figure 2).

Our results demonstrate that omalizumab treatment alone does not induce alterations in whole blood gene expression in patients with severe food allergy. This is not surprising given that these patients were unexposed to peanut allergen at the time of Baseline blood sampling, and any concomitant asthma, rhinitis or eczema were well controlled. However, since omalizumab can facilitate OIT, this drug likely allows for biological changes related to allergen tolerance during OIT. Our longitudinal analysis during pOIT + O identified up- and downregulation of several immune-related genes. CD278/ICOS (Inducible T-cell costimulatory) is expressed

This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. *Pediatric Allergy and Immunology* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

FIGURE 1 (A, B) Gene ontology (GO) biological process analysis of upregulated (A) and downregulated (B) genes. The x-axis shows the gene ratio of the overlapping genes of our gene list with the pathway gene set. The colour bar represents the adjusted p -value, and the circle size is the count of overlapping genes. (C, D) Boxplots display log2 expression values for six pOIT genes (C: upregulated, D: downregulated) throughout the treatment protocol at FDR $p < .05$. Red box: pOIT start, green box: Maintenance, blue box: Final. ORA = Over-representation analysis

on activated T cells and appears to play a role in directing effector T-cell differentiation and responses during inflammatory conditions.⁹ ICOS expression on T regulatory cells and T follicular helper cells may be involved in the allergic disease mechanism.¹⁰ In the pathway analyses, we observed significant enrichment for several GO biological process terms related to T-cell function and immune responses. Notably, we have previously described alterations in T-cell polyclonal *in vitro* activation during pOIT + O in the FASTX study,¹¹ and our cell fraction analyses also identified immunological

changes (Figure S2). Comparing our findings with data described by Watson et al⁸ suggests that pOIT + O may alter the expression level of genes that were found affected during an acute peanut allergic reaction.

The main limitations of this study are small sample size and lack of control subjects without omalizumab treatment, which may mask changes only associated with pOIT. Further, whole blood contains a highly heterogeneous cell population, which can only be partly accounted for by estimated cell fractions and our analysis may have

TABLE 1 FDR significant pOIT + O-related genes

Gene name	Full name	Ensembl.ID	Coefficient	Standard error	p-value	FDR
ASGR2	Asialoglycoprotein Receptor 2	ENSG00000161944	-0.3908	0.0809	4.68×10^{-05}	0.0496
GPBAR1	G Protein-Coupled Bile Acid Receptor 1	ENSG00000179921	-0.3264	0.0656	3.21×10^{-05}	0.0453
HM13	Minor Histocompatibility antigen H13	ENSG00000101294	-0.2385	0.0461	1.81×10^{-05}	0.0414
CALR	Calreticulin	ENSG00000179218	-0.2120	0.0370	3.67×10^{-06}	0.0386
RASSF4	Ras Association Domain Family Member 4	ENSG00000107551	-0.1865	0.0370	2.87×10^{-05}	0.0453
CFL1	Cofilin 1	ENSG00000172757	-0.1859	0.0331	5.85×10^{-06}	0.0386
KDELRL1	KDEL Endoplasmic Reticulum Retention Protein Receptor 1	ENSG00000105438	-0.1680	0.0300	6.83×10^{-06}	0.0386
YWHAE	Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon	ENSG00000108953	-0.1576	0.0296	1.19×10^{-05}	0.0414
USP44	Ubiquitin Specific Peptidase 44	ENSG00000136014	1.0998	0.2224	3.48×10^{-05}	0.0454
ICOS	Inducible T-Cell Costimulator	ENSG00000163600	0.4596	0.0957	4.69×10^{-05}	0.0496
CDKN2AIP	Cyclin-dependent Kinase Inhibitor 2A Interacting Protein	ENSG00000168564	0.3603	0.0705	2.27×10^{-05}	0.0428
ATM	ATM Serine/Threonine Kinase	ENSG00000149311	0.2913	0.0563	1.95×10^{-05}	0.0414
ADD3	Adducin 3	ENSG00000148700	0.2619	0.0524	3.18×10^{-05}	0.0453
GNG2	G Protein Subunit Gamma 2	ENSG00000186469	0.2436	0.0497	4.01×10^{-05}	0.0486
SEPTIN11	Septin 11	ENSG00000138758	0.1897	0.0358	1.47×10^{-05}	0.0414
OGT	O-Linked N-Acetylglucosamine (GlcNAc) Transferase	ENSG00000147162	0.1859	0.0354	1.56×10^{-05}	0.0414

FIGURE 2 Overlap of 108 genes from the FASTX pOIT study with the peanut-related genes found in Watson et al. at nominal $p < .005$. The y-axis represents changes in gene expression between the means at baseline and the 4-h time point of the peanut challenge in Watson et al, and the x-axis is effect size estimates from the mixed-effect model in the FASTX pOIT study. The green colour shows opposite direction, and the pink same direction

failed to detect important treatment-related changes connected specifically to peanut antigen-specific cells. In conclusion, omalizumab treatment alone does not alter the transcriptional signature

in peripheral blood of peanut allergic patients, but during pOIT + O, several immune-related signatures were observed. These results may provide insights into mechanisms of allergen tolerance.

FUNDING INFORMATION

The PERMEABLE consortium supported by ZonMW (456008004), the Swedish Research Council (2018-05619), the Ministry of Education, Science and Sport of the Republic of Slovenia (C3330-19-252012) and the German Ministry of Education and Research (BMBF) (FKZ01KU1909A), under the frame of the ERA PerMed JTC 2018 Call. Additional funding in the Online Appendix.

ACKNOWLEDGEMENTS

We thank all FASTX patients for their participation and the research staff at Forskningscentrum, Södersjukhuset.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

Sophia Björkander: Conceptualization (equal); data curation (equal); investigation (equal); methodology (equal); visualization (lead); writing–original draft (equal); writing–review and editing (equal). **Simon Kebede Merid:** Conceptualization (equal); data curation (equal); formal analysis (lead); investigation (equal); methodology (lead); software (lead); visualization (equal); writing–original draft (equal); writing–review and editing (equal). **David Brodin:** Conceptualization (equal); data curation (equal); methodology (equal); software (equal); writing–review and editing (equal). **Josef Brandström:** Conceptualization (equal); data curation (equal); investigation (equal); writing–review and editing (equal). **Fredrik Fagerström-Billai:** Conceptualization (equal); data curation (equal); formal analysis (equal); methodology (equal); software (equal); writing–review and editing (equal). **Marieke van der Heiden:** Conceptualization (equal); methodology (equal); writing–review and editing (equal). **Jon R. Konradsen:** Conceptualization (equal); data curation (equal); writing–review and editing (equal). **Michael Kabesch:** Conceptualization (equal); funding acquisition (equal); writing–review and editing (equal). **Cornelis M. van Drunen:** Conceptualization (equal); funding acquisition (equal); writing–review and editing (equal). **Korneliusz Golebski:** Conceptualization (equal); writing–review and editing (equal). **Anke H. Maitland-van der Zee:** Conceptualization (equal); funding acquisition (equal); writing–review and editing (equal). **Uroš Potočnik:** Conceptualization (equal); funding acquisition (equal); writing–review and editing (equal). **Susanne J. H. Vijverberg:** Conceptualization (equal); funding acquisition (equal); writing–review and editing (equal). **Anna Nopp:** Conceptualization (equal); data curation (equal); investigation (equal); resources (equal); writing–review and editing (equal). **Caroline Nilsson:** Conceptualization (equal); funding acquisition (equal); investigation (equal); resources (equal); writing–review and editing (equal). **Erik Melén:** Conceptualization (equal); data curation (equal); funding acquisition (equal); investigation (equal); methodology (equal); project administration (equal); supervision (lead); writing–original draft (equal); writing–review and editing (equal).

ETHICAL APPROVAL

The study was approved by the Ethics Committee in Stockholm: 2013/827-31/3, 2014/1980-32, 2016/1390-32, 2020-00807 and the Swedish Drug Agency: 5.1-2013-46183; the trial is registered at EudraCT: 2012-005625-78, ClinicalTrials.gov; NCT02402231. Patients and caregivers provided written informed consent.

PEER REVIEW

The peer review history for this article is available at <https://publons.com/publon/10.1111/pai.13682>.

Sophia Björkander¹

Simon Kebede Merid¹

David Brodin²

Josef Brandström^{3,4}

Fredrik Fagerström-Billai²

Marieke van der Heiden⁵

Jon R. Konradsen⁴

Michael Kabesch⁶

Cornelis M. van Drunen⁷

Korneliusz Golebski^{8,9}

Anke H. Maitland-van der Zee⁹

Uroš Potočnik^{10,11}

Susanne J. H. Vijverberg⁹

Anna Nopp^{1,12}

Caroline Nilsson^{1,12}

Erik Melén^{1,12}

¹Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden

²Bioinformatics and Expression Core Facility, Karolinska Institutet, Huddinge, Sweden

³Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden

⁴Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

⁵Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

⁶Department of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Regensburg, Germany

⁷Department of Otorhinolaryngology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

⁸Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

⁹Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

¹⁰Faculty of Medicine, Center for Human Molecular Genetics and Pharmacogenomics, University of Maribor, Maribor, Slovenia

¹¹Laboratory for Biochemistry, Molecular Biology and Genomics, Faculty for Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenia

¹²Sachs Children and Youth Hospital, Stockholm, Sweden

Correspondence

Erik Melén, Department of Clinical Science and Education,
Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.

Email: erik.melen@ki.se

Editor: Rachel Peters

Sophia Björkander and Simon Kebede Merid are equal
contributions.

ORCID

Simon Kebede Merid <https://orcid.org/0000-0001-5974-7676>

Michael Kabesch <https://orcid.org/0000-0003-0697-1871>

Susanne J. H. Vijverberg <https://orcid.org/0000-0002-4579-4081>

[org/0000-0002-4579-4081](https://orcid.org/0000-0002-4579-4081)

Caroline Nilsson <https://orcid.org/0000-0003-2040-8428>

Erik Melén <https://orcid.org/0000-0002-8248-0663>

REFERENCES

1. Vetander M, Protudjer JLP, Lilja G, et al. Anaphylaxis to foods in a population of adolescents: incidence, characteristics and associated risks. *Clin Exp Allergy*. 2016;46:1575-1587. <https://doi.org/10.1111/cea.12842>
2. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. *Lancet*. 2019;393:2222-2232. [https://doi.org/10.1016/S0140-6736\(19\)30420-9](https://doi.org/10.1016/S0140-6736(19)30420-9)
3. Fiocchi A, Artesani MC, Fierro V, et al. Oral immunotherapy for peanut allergy: the con argument. *World Allergy Organ J*. 2020;13:100445. <https://doi.org/10.1016/j.waojou.2020.100445>
4. Ramsey N, Berin MC. Pathogenesis of IgE-mediated food allergy and implications for future immunotherapeutics. *Pediatr Allergy Immunol*. 2021;32(7):1416-1425. <https://doi.org/10.1111/pai.13501>
5. Brandström J, Vetander M, Sundqvist A-C, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. *Clin Exp Allergy*. 2019;49:1328-1341. <https://doi.org/10.1111/cea.13469>
6. Brandström J, Vetander M, Lilja G, et al. Individually dosed omalizumab: an effective treatment for severe peanut allergy. *Clin Exp Allergy*. 2017;47:540-550. <https://doi.org/10.1111/cea.12862>
7. Nopp A, Cardell LO, Johansson SG, Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. *Allergy*. 2009;64:811-814. <https://doi.org/10.1111/j.1398-9995.2008.01900.x>
8. Watson CT, Cohain AT, Griffin RS, et al. Integrative transcriptomic analysis reveals key drivers of acute peanut allergic reactions. *Nat Commun*. 2017;8:1943. <https://doi.org/10.1038/s41467-017-02188-7>
9. Wikenheiser DJ, Stumhofer JS. ICOS co-stimulation: friend or foe? *Front Immunol*. 2016;7. <https://doi.org/10.3389/fimmu.2016.00304>
10. Li DY, Xiong XZ. ICOS(+) tregs: a functional subset of tregs in immune diseases. *Front Immunol*. 2020;11:2104. <https://doi.org/10.3389/fimmu.2020.02104>
11. Heiden M, Nopp A, Brandström J, et al. A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut-allergic adolescents. *Scand J Immunol*. 2021;93:e13005. <https://doi.org/10.1111/sji.13005>

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.